The veterinary rapid tests market was valued at USD 953.2 million in 2025 and is projected to reach USD 2.3 billion by 2035, expanding at a 9.1% CAGR from 2026 to 2035. According to the latest report published by Global Market Insights Inc., demand is shifting from centralized laboratory diagnostics toward point-of-care testing across companion animal clinics, veterinary hospitals, homecare settings, and livestock disease-surveillance programs. Rapid tests address the clinical and operational cost of delayed results, particularly where treatment, isolation, or field-level biosecurity decisions cannot wait for reference-laboratory turnaround. The market increasingly depends on recurring consumable-kit demand rather than one-time instrument sales, although reader platforms remain strategically relevant for larger practices and multi-site veterinary groups.
The market covers rapid diagnostic kits and reader-supported rapid-testing platforms used to detect viral, parasitic, bacterial, allergy-related, and other animal health conditions. It includes antigen-based, antibody-based, and mixed testing formats across companion animals and livestock animals. Blood, feces, serum, plasma, urine, and other biological sample types fall within scope. Veterinary clinics, veterinary hospitals, homecare settings, and other institutional end users form the primary demand channels.
Market estimates use a triangulated approach combining product-category revenue, channel demand, regional veterinary-care capacity, company positioning, disease-surveillance requirements, and primary-research inputs. The 2025 base estimate is expressed in USD million, with all forecast values extending through 2035. Revenue-share analysis allocates market value across product type, test type, application, animal type, sample type, end use, and geography without creating unsupported intermediate-year values.
GMI Analyst View
Veterinary rapid testing will remain one of the most durable point-of-care diagnostic categories through 2035 because clinical workflows increasingly value same-appointment decisions. Companion animal demand creates the largest recurring revenue pool, while livestock surveillance creates institutional demand that is less dependent on discretionary pet-owner spending. The more consequential shift is the move from single-analyte visual tests toward multiplex and reader-connected formats that improve diagnostic consistency and expand data capture. By 2028, suppliers with both consumable-kit breadth and clinically useful digital-reader platforms will have a stronger position in consolidated veterinary-practice networks.
Key Drivers
Driver
Approx. CAGR Impact
Impact
Timeline
Growing companion animal population
+1.8-2.2%
Global-concentrated in North America, Europe, and urban Asia Pacific
Medium term (2-4 years)
Increasing prevalence of zoonotic diseases in animals
+1.6-2.0%
Global-led by livestock-intensive APAC and MEA surveillance programs
Short term (≤2 years)
Rising demand for rapid diagnosis over conventional methods
+1.5-1.9%
North America and Europe-strongest in clinic and hospital workflows
Short term (≤2 years)
Increasing pet ownership in emerging economies
+1.4-1.8%
Asia Pacific and Latin America-concentrated in urban companion-animal care
Long term (≥4 years)
Growing Number of Companion Animal Population
Companion animal ownership supports recurring diagnostic demand because routine testing is increasingly integrated into preventive-care visits. Approximately 70% of U.S. households owned at least one pet in 2024, with dogs and cats comprising most of the companion animal base.[1] Pet owners in urban markets are allocating more spending toward earlier diagnosis, rather than treatment after disease progression. Rapid test kits fit this pattern because practitioners can provide results during the same appointment. The companion animal segment accounted for 66.1% of market revenue in 2025, and dogs generated 56.4% of companion animal diagnostic revenue.
Increasing Prevalence of Zoonotic Diseases in Animals
Zoonotic disease monitoring creates demand beyond the elective companion-care segment. Approximately 60% of known human infectious diseases originate in animals, reinforcing the importance of veterinary disease detection within One Health frameworks.[2] Rapid antigen and antibody formats support field-level screening for conditions including Brucellosis, Leptospirosis, Rabies, and avian influenza. National surveillance programs create larger, recurring procurement requirements for livestock testing. This demand is particularly relevant in regions with dense animal populations and frequent animal-human contact.
Rising Demand for Rapid Test Diagnosis Over Other Tests
Rapid tests produce results within 10-30 minutes, compared with 24-72 hours for conventional culture-based or PCR laboratory testing.[3] The speed advantage allows treatment protocols and isolation decisions to begin during the clinical encounter. Clinics with limited laboratory capacity can use rapid kits without extensive equipment investments. Lateral flow formats also reduce the administrative and logistical burden of specimen referral. This operational benefit supports adoption across clinics, hospitals, mobile veterinary services, and livestock operations.
Increasing Pet Ownership
Pet adoption is generating new veterinary-health demand in Brazil, China, and India. Rising disposable income in middle-income economies is associated with higher expenditure on companion animal care, including preventive diagnostic services. These countries extend the addressable market beyond North America and Western Europe. Homecare and clinic-based testing both benefit as pet owners become more familiar with routine animal-health monitoring. The long-term commercial opportunity depends on price-accessible kits and broader veterinary distribution coverage.
Key Restraints
Challenge
Approx. CAGR Impact
Impact
Timeline
Limited diagnostic infrastructure
-1.5-2.0%
MEA, Latin America, and rural APAC-constrained by logistics and service coverage
Long term (≥4 years)
Lack of awareness for veterinary health in underdeveloped countries
-1.2-1.6%
Sub-Saharan Africa and South and Southeast Asia-concentrated among underserved owners and farmers
Medium term (2-4 years)
Increasing cost of animal healthcare
-1.3-1.7%
Global-disproportionate effect on cost-sensitive pet owners and small livestock operators
Short term (≤2 years)
Limited Number of Infrastructures for Veterinary Diagnosis
Rural and lower-income markets often lack veterinary diagnostic facilities, cold-chain reliability, trained staff, and consistent product supply. Portability makes lateral flow kits more accessible than laboratory systems, but it does not eliminate shortages in veterinary service coverage. This constraint is most apparent across portions of sub-Saharan Africa, South Asia, Southeast Asia, and Latin America. Suppliers face uneven demand visibility where distributor coverage remains weak. Infrastructure expansion will determine how much of the theoretical emerging-market opportunity becomes commercially reachable through 2030.
Lack of Awareness for Veterinary Health in Underdeveloped Countries
Preventive diagnostics remain underused where livestock farmers and pet owners rely primarily on reactive treatment. Limited animal-health literacy suppresses testing frequency even when products are available. The resulting low volume discourages distributors from carrying broad diagnostic portfolios, reinforcing access gaps. Government outreach and livestock-surveillance initiatives can partially change this demand pattern. The market will expand more slowly in geographies where education programs and veterinary networks remain underfunded.
Increasing Cost of Animal Healthcare
Higher veterinary-service costs and diagnostic consumable prices create adoption barriers for cost-sensitive owners and small-scale livestock operators. Cost sensitivity remains a recurring barrier to veterinary-care utilization. Suppliers must balance performance improvements against test affordability. Tiered pricing, simplified stock-keeping units, and distributor-led access programs are important commercial responses. The restraint is strongest where diagnostics are paid directly by owners rather than procured through public surveillance programs.
GMI Analyst View
Driver strength exceeds restraint pressure through the forecast period, but growth will not be uniform across channels or regions. Companion animal testing and disease-surveillance procurement will remain the principal demand engines, while infrastructure and affordability will constrain penetration in lower-income markets. The second-order effect of faster clinic diagnosis is improved treatment planning and fewer repeat visits, which makes rapid testing more valuable than a standalone consumable purchase. By 2030, suppliers that combine entry-level visual tests with scalable reader platforms will be better positioned to serve both cost-sensitive and advanced-care settings.
Veterinary Rapid Tests Market Segment Analysis
By Product Type
Rapid test kits accounted for 67.6% of revenue in 2025 and are projected to expand at a 9.9% CAGR through 2035. Their recurring consumable profile gives the category a more stable revenue base than reader hardware. IDEXX SNAP® Pro and BioNote Anigen Rapid represent major kit platforms across companion animal and livestock testing. Broad pathogen coverage and lower equipment requirements support use in smaller clinics, mobile services, and field operations.
Rapid test readers held 32.4% share and are projected to grow at a 7.0% CAGR, supported by demand for standardized results and expanded analyte panels. IDEXX Catalyst® and Heska Element DC5x® illustrate the reader-supported shift toward semi-quantitative and connected diagnostics.
By Test Type
Antigen-based rapid tests held 49.8% of market revenue in 2025 and are projected to expand at a 10.1% CAGR through 2035. These tests identify pathogen structural proteins, making them clinically useful for active-infection decisions. IDEXX SNAP Parvo and Fassisi FASTest PARVO Strip serve established companion-animal antigen-testing needs. Antibody-based tests held 33.7% share and are projected to grow at 8.5%, particularly for seroprevalence surveillance, post-vaccination monitoring, and chronic disease screening. Mixed tests accounted for 16.4% share and integrate antigen and antibody detection in a single workflow, including FeLV/FIV co-testing applications.
By Application
Viral testing accounted for 39.9% of market revenue in 2025 and is projected to grow at a 9.7% CAGR through 2035. Canine parvovirus, distemper, feline panleukopenia, and respiratory pathogens require rapid identification because treatment and isolation decisions are time-sensitive. IDEXX SNAP Parvo and BioNote Anigen Rapid Canine Parvovirus Ag Test support this demand. Bacterial diagnostics represented 25.1% of revenue and are supported by Lyme disease, Brucella, and Clostridium testing. Parasitic diagnostics accounted for 18.2%, with heartworm, Giardia, and intestinal-parasite screening forming major applications. Allergy testing represented 10.5% and is gaining relevance as pet owners seek earlier assessment of food and environmental sensitivities.
By Animal Type
Companion animals represented 66.1% of market revenue in 2025 and are projected to expand at a 10.2% CAGR through 2035. Dogs accounted for 56.4% of companion-animal revenue and are projected to grow at an 11.3% CAGR, supported by the broad range of canine pathogen and chronic-condition tests. Cats represented 29.9% of companion-animal revenue, with FeLV/FIV combination testing among the highest-volume product categories. Horses accounted for 8.8%, supported by field testing for equine infectious anemia and equine influenza. Livestock animals accounted for 33.9% of total revenue and are driven by surveillance mandates rather than owner-elected preventive testing. Cattle led livestock revenue at 47.1%, followed by swine at 27.3% and poultry at 16.9%.
By Sample Type
Blood-based tests accounted for 28.0% of revenue in 2025 and are projected to expand at a 10.1% CAGR through 2035. Whole blood supports heartworm, FeLV/FIV, and Lyme disease testing without extensive sample preparation. Plasma represented 25.7% of revenue, while serum held 22.6% and remains relevant for livestock surveillance protocols. Feces-based testing accounted for 13.0%, supported by Giardia, Cryptosporidium, and canine parvovirus testing. Urine-based formats represented 8.3% and are used in Leptospirosis detection and renal-health monitoring. Other sample types, including nasal and oropharyngeal swabs, ocular secretions, and dairy-cattle milk samples, accounted for 2.4%.
By End Use
Veterinary clinics accounted for 39.7% of market revenue in 2025 and are projected to expand at an 8.6% CAGR through 2035. Clinics rely on point-of-care tests to provide same-appointment results without maintaining full laboratory infrastructure.
Veterinary hospitals represented 31.5% of revenue and are more likely to deploy reader-based multiplex systems alongside broader in-house testing capabilities. Homecare settings accounted for 21.9% and are projected to grow at the highest end-use CAGR of 10.0%. Consumer-oriented visual-read kits and simplified instructions are widening access to preliminary pet-health screening. Other end users, including academic institutions, government agencies, animal shelters, and contract research organizations, represented 6.9%.
GMI Analyst View
Segment leadership is increasingly determined by workflow fit rather than pathogen coverage alone. Consumable kits will retain the largest share because they serve high-volume screening needs without major capital expenditures. Reader platforms will remain important where practices require standardized results, multi-site data visibility, and broader analyte menus. Primary research conducted across 35 veterinary dermatology practices in North America and Europe in Q2 2026 found that 58% reported increased client-initiated requests for allergy diagnostics compared with 2023, with rapid IgE screening gaining traction before immunotherapy planning. Through 2030, companion-animal diagnostic growth will continue to outpace livestock testing, although livestock surveillance will remain strategically important for public-health procurement.
Veterinary Rapid Tests Market Regional Analysis
North America
North America accounted for 40.5% of global revenue in 2025 and is projected to grow at an 8.3% CAGR through 2035. The U.S. leads regional demand, supported by companion-animal ownership, established veterinary-practice networks, and dense supplier distribution. Approximately 70% of U.S. households owned at least one pet in 2024. IDEXX Laboratories and Heska Corporation maintain strong commercial relationships with veterinary practices across the region. USDA APHIS accelerated attention to field-deployable avian influenza testing after H5N1 detections in U.S. dairy cattle herds.[6] Canada remains the second-largest regional market, with recurring surveillance activity supported by the Canadian Food Inspection Agency.[7]
Europe
Europe accounted for 26.9% of revenue in 2025 and is projected to expand at a 9.0% CAGR through 2035. Germany, the UK, France, the Netherlands, Spain, and Italy form the region's core markets. Regulation (EU) 2016/429 established harmonized animal-health surveillance and reporting requirements across EU member states.[4] MEGACOR Diagnostik, Fassisi, INDICAL Bioscience, BioChek, and Agrolabo benefit from proximity to European distribution and surveillance networks. Germany and France support established companion-animal care markets, while the UK remains served through existing European diagnostic distribution relationships. The region's constraint is a mature market structure that limits the pace of volume expansion relative to Asia Pacific.
Asia Pacific
Asia Pacific is projected to grow at the highest regional CAGR of 10.4% through 2035. China is the largest regional national market, supported by a companion animal population exceeding 130 million animals in 2024. India's NADCP has supported field testing for FMD and Brucellosis since 2019.[5] Japan and South Korea represent advanced reader-platform markets, while BioNote has built an Anigen Rapid distribution network across more than 50 countries as of 2025. China, India, Japan, Australia, and South Korea each contribute distinct demand drivers across companion-animal care, government surveillance, and regional manufacturing. Price sensitivity outside leading metropolitan markets remains an important commercial constraint.
Latin America
Brazil is the principal emerging market in Latin America, supported by pet adoption and rising demand for companion animal healthcare. Mexico and Argentina contribute additional livestock and companion-animal testing demand. The region benefits from an expanding urban pet-care base, although uneven veterinary infrastructure and affordability constrain rural adoption. Virbac's commercial reach in Latin America supports regional product access. Tiered test formats and distributor partnerships will remain important for expanding penetration through 2030.
Middle East and Africa
Middle East and Africa demand is concentrated in institutional livestock surveillance, selected urban companion-animal markets, and field-based disease screening. South Africa, Saudi Arabia, and the UAE represent the named regional markets. Infrastructure limitations, supply reliability, and training shortages constrain broader rapid-test adoption across lower-income markets. Zoonotic disease monitoring and livestock-health programs create the clearest near-term demand opportunities. Portable tests offer a practical advantage where centralized laboratory access is limited, but adoption remains dependent on veterinary-service coverage.
GMI Analyst View
Regional divergence will remain pronounced through 2035. North America will retain the largest revenue base because of practice density and companion-animal spending, while Asia Pacific will gain share through higher growth in pet ownership, surveillance investment, and local manufacturing. Europe will remain commercially important because regulation supports structured testing demand. Emerging markets will not follow a uniform adoption path: urban clinics will adopt accessible rapid-kit formats first, while rural growth will depend on public programs and distribution infrastructure.
The veterinary rapid tests market is moderately concentrated. IDEXX Laboratories held an estimated 16.7% share of global revenue in 2025, while IDEXX Laboratories, Zoetis, Thermo Fisher Scientific, Virbac, and Heska Corporation (Mars Inc.) collectively held 51.4%. The leadership group combines broad product portfolios, established veterinary relationships, distribution reach, and regulatory capability.
IDEXX Laboratories remains the market leader through its SNAP® test family, SNAP® Pro reader, broader in-clinic diagnostics, reference laboratories, practice-management software, and imaging ecosystem. This combination creates switching costs for practices that already rely on integrated IDEXX workflows. Zoetis leverages longstanding therapeutic and vaccine relationships to expand Vcheck diagnostics in companion-animal and livestock channels. Thermo Fisher Scientific provides reagent, assay, and life-science supply-chain capabilities that support its own veterinary activity and upstream component supply to smaller manufacturers.
Virbac has commercial depth across Europe, Latin America, and Asia Pacific. Heska Corporation operates within Mars Petcare following its December 2021 acquisition, with Element DC5x®, Element i+®, and Solo Step CH Canine Heartworm Antigen Test supporting its reader-based and rapid-kit presence. Primary research from Q1 2026 conversations with 40 veterinary product distributors across North America, Europe, and Asia Pacific identified product breadth, regulatory certification coverage, and regional service responsiveness as the leading supplier-selection criteria.
Recent Industry Developments
May 2025: IDEXX Laboratories announced commercial expansion of SNAP® multiplex testing capabilities for canine respiratory pathogens, including *Bordetella bronchiseptica* and canine influenza virus. The development broadens same-visit respiratory diagnostic options for North American and European clinics.
Mar 2025: Zoetis expanded its Vcheck diagnostic analyzer platform with NT-proBNP and cardiac troponin I panels for dogs. The addition extends rapid in-clinic testing into companion-animal cardiology.
Jan 2025: BioNote received regulatory clearance in South Korea and multiple Southeast Asian markets for expanded Anigen Rapid applications, including FeLV/FIV co-infection detection. The clearance supports wider feline diagnostic access in Asia Pacific.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Authors: Monali Tayade, Shishanka Wangnoo
Veterinary Rapid Tests Market Scope
Veterinary Rapid Tests Market Size
Veterinary Rapid Tests Market Trends
Veterinary Rapid Tests Market Analysis
Veterinary Rapid Tests Market Share
Report Content
Chapter 1 Methodology & Scope
1.1 Market scope and definition
1.2 Research approach
1.3 Quality commitments
1.3.1 GMI AI policy and data integrity commitment
1.3.1.1 Source consistency protocol
1.4 Research trail and confidence scoring
1.4.1 Research trail components
1.4.2 Scoring components
1.5 Data collection
1.5.1 Partial list of primary sources
1.6 Data mining sources
1.6.1 Paid sources
1.6.1.1 Sources, by region
1.7 Base estimates and calculations
1.7.1 Revenue share analysis
1.7.2 Base year calculation
1.8 Forecast model
1.9 Research transparency addendum
1.9.1 Source attribution framework
1.9.2 Quality assurance metrics
1.9.3 Our commitment to trust
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
2.2 Key market trends
2.2.1 Regional trends
2.2.2 Product type trends
2.2.3 Test type trends
2.2.4 Application trends
2.2.5 Animal type trends
2.2.6 Sample type trends
2.2.7 End use trends
2.3 CXO perspectives: Strategic imperatives
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing number of companion animal population
3.2.1.2 Increasing prevalence of zoonotic diseases in animals
3.2.1.3 Rising demand for rapid test diagnosis over other tests
3.2.1.4 Increasing pet ownership
3.2.2 Industry pitfalls & challenges
3.2.2.1 Limited number of infrastructures for veterinary diagnosis
3.2.2.2 Lack of awareness for veterinary health in underdeveloped countries
3.2.2.3 Increasing cost of animal healthcare
3.2.3 Market opportunities
3.2.3.1 Development of multiplex and portable rapid testing solutions
3.2.3.2 Expansion of veterinary diagnostics in emerging and rural markets
3.3 Growth potential analysis
3.4 Technology landscape
3.4.1 Current technology
3.4.2 Emerging technologies
3.5 Pricing analysis (Driven by Primary Research)
3.6 Regulatory landscape (Driven by primary research)
3.6.1 North America
3.6.2 Europe
3.6.3 Asia Pacific
3.6.4 Latin America
3.6.5 Middle East and Africa
3.7 Porter’s analysis
3.8 PESTEL analysis
3.9 Impact of AI and generative AI on the market
3.10 Future market trends (Driven by primary research)
3.11 Pet population statistics
Chapter 4 Competitive Landscape, 2025
4.1 Introduction
4.2 Company market share analysis
4.2.1 North America
4.2.2 Europe
4.2.3 Asia Pacific
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Key developments
4.6.1 Merger and acquisition
4.6.2 Partnership and collaboration
4.6.3 New product launches
4.6.4 Expansion plans
Chapter 5 Market Estimates and Forecast, By Product Type, 2022 — 2035 ($ Mn)
5.1 Key trends
5.2 Rapid test kits
5.3 Rapid test readers
Chapter 6 Market Estimates and Forecast, By Test Type, 2022 — 2035 ($ Mn)
6.1 Key trends
6.2 Antigen based rapid test
6.3 Antibody-based rapid test
6.4 Mixed tests
Chapter 7 Market Estimates and Forecast, By Application, 2022 — 2035 ($ Mn)
7.1 Key trends
7.2 Viral
7.3 Parasitic
7.4 Bacterial
7.5 Allergies
7.6 Other applications
Chapter 8 Market Estimates and Forecast, By Animal Type, 2022 — 2035 ($ Mn)
8.1 Key trends
8.2 Companion animals
8.2.1 Dogs
8.2.2 Cats
8.2.3 Horses
8.2.4 Other companion animals
8.3 Livestock animals
8.3.1 Cattle
8.3.2 Swine
8.3.3 Poultry
8.3.4 Other livestock animals
Chapter 9 Market Estimates and Forecast, By Sample Type, 2022 — 2035 ($ Mn)
9.1 Key trends
9.2 Blood
9.3 Feces
9.4 Serum
9.5 Plasma
9.6 Urine
9.7 Other sample types
Chapter 10 Market Estimates and Forecast, By End Use, 2022 — 2035 ($ Mn)
10.1 Key trends
10.2 Homecare settings
10.3 Veterinary hospitals
10.4 Veterinary clinics
10.5 Other end users
Chapter 11 Market Estimates and Forecast, By Region, 2022 — 2035 ($ Mn)
11.1 Key trends
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 France
11.3.4 Spain
11.3.5 Italy
11.3.6 Netherlands
11.4 Asia Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 Australia
11.4.5 South Korea
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Argentina
11.6 Middle East and Africa
11.6.1 South Africa
11.6.2 Saudi Arabia
11.6.3 UAE
Chapter 12 Company Profiles
Don't see your key competitors?
The companies listed in this report are a curated selection - not the full competitive universe.
Our market revenue calculations use a bottom-up methodology that accounts for all players across all regions - including manufacturers, distributors, and specialists not individually profiled. The profiles section spotlights strategically significant players; it does not define the scope of our market sizing.
Your competitive landscape may also include
Regional or domestic-only leaders not in the global top tier
Distributors and channel partners who control market access
Emerging disruptors, startups, or adjacent-industry entrants
Niche players focused on a specific application or end-use
Free customization - up to 20% of report value
Need specific data? Request customization and get the insights tailored to your exact requirements.
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at[email protected]
Over 70% of our clients customize reports to fit their needs. Please tell us how you would like to customize yours below
Share Content
Add Citations
Monali Tayade. 2026, August. Veterinary Rapid Tests Market - By Product Type, By Test Type, By Application, By Animal Type, By Sample Type, By End Use, Growth Forecast, 2026 - 2035 (Report ID: GMI3455). Global Market Insights Inc. Retrieved October 16, 2026, from https://www.gminsights.com/toc/details/veterinary-rapid-tests-market
Veterinary Rapid Tests Market
Get a free sample of this report
Get a free sample of this report Veterinary Rapid Tests Market
Is your requirement urgent? Please give us your business email for a speedy delivery!
Veterinary Rapid Tests Market Size
The veterinary rapid tests market was valued at USD 953.2 million in 2025 and is projected to reach USD 2.3 billion by 2035, expanding at a 9.1% CAGR from 2026 to 2035. According to the latest report published by Global Market Insights Inc., demand is shifting from centralized laboratory diagnostics toward point-of-care testing across companion animal clinics, veterinary hospitals, homecare settings, and livestock disease-surveillance programs. Rapid tests address the clinical and operational cost of delayed results, particularly where treatment, isolation, or field-level biosecurity decisions cannot wait for reference-laboratory turnaround. The market increasingly depends on recurring consumable-kit demand rather than one-time instrument sales, although reader platforms remain strategically relevant for larger practices and multi-site veterinary groups.
The market covers rapid diagnostic kits and reader-supported rapid-testing platforms used to detect viral, parasitic, bacterial, allergy-related, and other animal health conditions. It includes antigen-based, antibody-based, and mixed testing formats across companion animals and livestock animals. Blood, feces, serum, plasma, urine, and other biological sample types fall within scope. Veterinary clinics, veterinary hospitals, homecare settings, and other institutional end users form the primary demand channels.
Market estimates use a triangulated approach combining product-category revenue, channel demand, regional veterinary-care capacity, company positioning, disease-surveillance requirements, and primary-research inputs. The 2025 base estimate is expressed in USD million, with all forecast values extending through 2035. Revenue-share analysis allocates market value across product type, test type, application, animal type, sample type, end use, and geography without creating unsupported intermediate-year values.
GMI Analyst View
Veterinary rapid testing will remain one of the most durable point-of-care diagnostic categories through 2035 because clinical workflows increasingly value same-appointment decisions. Companion animal demand creates the largest recurring revenue pool, while livestock surveillance creates institutional demand that is less dependent on discretionary pet-owner spending. The more consequential shift is the move from single-analyte visual tests toward multiplex and reader-connected formats that improve diagnostic consistency and expand data capture. By 2028, suppliers with both consumable-kit breadth and clinically useful digital-reader platforms will have a stronger position in consolidated veterinary-practice networks.
Key Drivers
Growing Number of Companion Animal Population
Companion animal ownership supports recurring diagnostic demand because routine testing is increasingly integrated into preventive-care visits. Approximately 70% of U.S. households owned at least one pet in 2024, with dogs and cats comprising most of the companion animal base.[1] Pet owners in urban markets are allocating more spending toward earlier diagnosis, rather than treatment after disease progression. Rapid test kits fit this pattern because practitioners can provide results during the same appointment. The companion animal segment accounted for 66.1% of market revenue in 2025, and dogs generated 56.4% of companion animal diagnostic revenue.
Increasing Prevalence of Zoonotic Diseases in Animals
Zoonotic disease monitoring creates demand beyond the elective companion-care segment. Approximately 60% of known human infectious diseases originate in animals, reinforcing the importance of veterinary disease detection within One Health frameworks.[2] Rapid antigen and antibody formats support field-level screening for conditions including Brucellosis, Leptospirosis, Rabies, and avian influenza. National surveillance programs create larger, recurring procurement requirements for livestock testing. This demand is particularly relevant in regions with dense animal populations and frequent animal-human contact.
Rising Demand for Rapid Test Diagnosis Over Other Tests
Rapid tests produce results within 10-30 minutes, compared with 24-72 hours for conventional culture-based or PCR laboratory testing.[3] The speed advantage allows treatment protocols and isolation decisions to begin during the clinical encounter. Clinics with limited laboratory capacity can use rapid kits without extensive equipment investments. Lateral flow formats also reduce the administrative and logistical burden of specimen referral. This operational benefit supports adoption across clinics, hospitals, mobile veterinary services, and livestock operations.
Increasing Pet Ownership
Pet adoption is generating new veterinary-health demand in Brazil, China, and India. Rising disposable income in middle-income economies is associated with higher expenditure on companion animal care, including preventive diagnostic services. These countries extend the addressable market beyond North America and Western Europe. Homecare and clinic-based testing both benefit as pet owners become more familiar with routine animal-health monitoring. The long-term commercial opportunity depends on price-accessible kits and broader veterinary distribution coverage.
Key Restraints
Limited Number of Infrastructures for Veterinary Diagnosis
Rural and lower-income markets often lack veterinary diagnostic facilities, cold-chain reliability, trained staff, and consistent product supply. Portability makes lateral flow kits more accessible than laboratory systems, but it does not eliminate shortages in veterinary service coverage. This constraint is most apparent across portions of sub-Saharan Africa, South Asia, Southeast Asia, and Latin America. Suppliers face uneven demand visibility where distributor coverage remains weak. Infrastructure expansion will determine how much of the theoretical emerging-market opportunity becomes commercially reachable through 2030.
Lack of Awareness for Veterinary Health in Underdeveloped Countries
Preventive diagnostics remain underused where livestock farmers and pet owners rely primarily on reactive treatment. Limited animal-health literacy suppresses testing frequency even when products are available. The resulting low volume discourages distributors from carrying broad diagnostic portfolios, reinforcing access gaps. Government outreach and livestock-surveillance initiatives can partially change this demand pattern. The market will expand more slowly in geographies where education programs and veterinary networks remain underfunded.
Increasing Cost of Animal Healthcare
Higher veterinary-service costs and diagnostic consumable prices create adoption barriers for cost-sensitive owners and small-scale livestock operators. Cost sensitivity remains a recurring barrier to veterinary-care utilization. Suppliers must balance performance improvements against test affordability. Tiered pricing, simplified stock-keeping units, and distributor-led access programs are important commercial responses. The restraint is strongest where diagnostics are paid directly by owners rather than procured through public surveillance programs.
GMI Analyst View
Driver strength exceeds restraint pressure through the forecast period, but growth will not be uniform across channels or regions. Companion animal testing and disease-surveillance procurement will remain the principal demand engines, while infrastructure and affordability will constrain penetration in lower-income markets. The second-order effect of faster clinic diagnosis is improved treatment planning and fewer repeat visits, which makes rapid testing more valuable than a standalone consumable purchase. By 2030, suppliers that combine entry-level visual tests with scalable reader platforms will be better positioned to serve both cost-sensitive and advanced-care settings.
Veterinary Rapid Tests Market Segment Analysis
By Product Type
Rapid test kits accounted for 67.6% of revenue in 2025 and are projected to expand at a 9.9% CAGR through 2035. Their recurring consumable profile gives the category a more stable revenue base than reader hardware. IDEXX SNAP® Pro and BioNote Anigen Rapid represent major kit platforms across companion animal and livestock testing. Broad pathogen coverage and lower equipment requirements support use in smaller clinics, mobile services, and field operations.
Rapid test readers held 32.4% share and are projected to grow at a 7.0% CAGR, supported by demand for standardized results and expanded analyte panels. IDEXX Catalyst® and Heska Element DC5x® illustrate the reader-supported shift toward semi-quantitative and connected diagnostics.
By Test Type
Antigen-based rapid tests held 49.8% of market revenue in 2025 and are projected to expand at a 10.1% CAGR through 2035. These tests identify pathogen structural proteins, making them clinically useful for active-infection decisions. IDEXX SNAP Parvo and Fassisi FASTest PARVO Strip serve established companion-animal antigen-testing needs. Antibody-based tests held 33.7% share and are projected to grow at 8.5%, particularly for seroprevalence surveillance, post-vaccination monitoring, and chronic disease screening. Mixed tests accounted for 16.4% share and integrate antigen and antibody detection in a single workflow, including FeLV/FIV co-testing applications.
By Application
Viral testing accounted for 39.9% of market revenue in 2025 and is projected to grow at a 9.7% CAGR through 2035. Canine parvovirus, distemper, feline panleukopenia, and respiratory pathogens require rapid identification because treatment and isolation decisions are time-sensitive. IDEXX SNAP Parvo and BioNote Anigen Rapid Canine Parvovirus Ag Test support this demand. Bacterial diagnostics represented 25.1% of revenue and are supported by Lyme disease, Brucella, and Clostridium testing. Parasitic diagnostics accounted for 18.2%, with heartworm, Giardia, and intestinal-parasite screening forming major applications. Allergy testing represented 10.5% and is gaining relevance as pet owners seek earlier assessment of food and environmental sensitivities.
By Animal Type
Companion animals represented 66.1% of market revenue in 2025 and are projected to expand at a 10.2% CAGR through 2035. Dogs accounted for 56.4% of companion-animal revenue and are projected to grow at an 11.3% CAGR, supported by the broad range of canine pathogen and chronic-condition tests. Cats represented 29.9% of companion-animal revenue, with FeLV/FIV combination testing among the highest-volume product categories. Horses accounted for 8.8%, supported by field testing for equine infectious anemia and equine influenza. Livestock animals accounted for 33.9% of total revenue and are driven by surveillance mandates rather than owner-elected preventive testing. Cattle led livestock revenue at 47.1%, followed by swine at 27.3% and poultry at 16.9%.
By Sample Type
Blood-based tests accounted for 28.0% of revenue in 2025 and are projected to expand at a 10.1% CAGR through 2035. Whole blood supports heartworm, FeLV/FIV, and Lyme disease testing without extensive sample preparation. Plasma represented 25.7% of revenue, while serum held 22.6% and remains relevant for livestock surveillance protocols. Feces-based testing accounted for 13.0%, supported by Giardia, Cryptosporidium, and canine parvovirus testing. Urine-based formats represented 8.3% and are used in Leptospirosis detection and renal-health monitoring. Other sample types, including nasal and oropharyngeal swabs, ocular secretions, and dairy-cattle milk samples, accounted for 2.4%.
By End Use
Veterinary clinics accounted for 39.7% of market revenue in 2025 and are projected to expand at an 8.6% CAGR through 2035. Clinics rely on point-of-care tests to provide same-appointment results without maintaining full laboratory infrastructure.
Veterinary hospitals represented 31.5% of revenue and are more likely to deploy reader-based multiplex systems alongside broader in-house testing capabilities. Homecare settings accounted for 21.9% and are projected to grow at the highest end-use CAGR of 10.0%. Consumer-oriented visual-read kits and simplified instructions are widening access to preliminary pet-health screening. Other end users, including academic institutions, government agencies, animal shelters, and contract research organizations, represented 6.9%.
GMI Analyst View
Segment leadership is increasingly determined by workflow fit rather than pathogen coverage alone. Consumable kits will retain the largest share because they serve high-volume screening needs without major capital expenditures. Reader platforms will remain important where practices require standardized results, multi-site data visibility, and broader analyte menus. Primary research conducted across 35 veterinary dermatology practices in North America and Europe in Q2 2026 found that 58% reported increased client-initiated requests for allergy diagnostics compared with 2023, with rapid IgE screening gaining traction before immunotherapy planning. Through 2030, companion-animal diagnostic growth will continue to outpace livestock testing, although livestock surveillance will remain strategically important for public-health procurement.
Veterinary Rapid Tests Market Regional Analysis
North America
North America accounted for 40.5% of global revenue in 2025 and is projected to grow at an 8.3% CAGR through 2035. The U.S. leads regional demand, supported by companion-animal ownership, established veterinary-practice networks, and dense supplier distribution. Approximately 70% of U.S. households owned at least one pet in 2024. IDEXX Laboratories and Heska Corporation maintain strong commercial relationships with veterinary practices across the region. USDA APHIS accelerated attention to field-deployable avian influenza testing after H5N1 detections in U.S. dairy cattle herds.[6] Canada remains the second-largest regional market, with recurring surveillance activity supported by the Canadian Food Inspection Agency.[7]
Europe
Europe accounted for 26.9% of revenue in 2025 and is projected to expand at a 9.0% CAGR through 2035. Germany, the UK, France, the Netherlands, Spain, and Italy form the region's core markets. Regulation (EU) 2016/429 established harmonized animal-health surveillance and reporting requirements across EU member states.[4] MEGACOR Diagnostik, Fassisi, INDICAL Bioscience, BioChek, and Agrolabo benefit from proximity to European distribution and surveillance networks. Germany and France support established companion-animal care markets, while the UK remains served through existing European diagnostic distribution relationships. The region's constraint is a mature market structure that limits the pace of volume expansion relative to Asia Pacific.
Asia Pacific
Asia Pacific is projected to grow at the highest regional CAGR of 10.4% through 2035. China is the largest regional national market, supported by a companion animal population exceeding 130 million animals in 2024. India's NADCP has supported field testing for FMD and Brucellosis since 2019.[5] Japan and South Korea represent advanced reader-platform markets, while BioNote has built an Anigen Rapid distribution network across more than 50 countries as of 2025. China, India, Japan, Australia, and South Korea each contribute distinct demand drivers across companion-animal care, government surveillance, and regional manufacturing. Price sensitivity outside leading metropolitan markets remains an important commercial constraint.
Latin America
Brazil is the principal emerging market in Latin America, supported by pet adoption and rising demand for companion animal healthcare. Mexico and Argentina contribute additional livestock and companion-animal testing demand. The region benefits from an expanding urban pet-care base, although uneven veterinary infrastructure and affordability constrain rural adoption. Virbac's commercial reach in Latin America supports regional product access. Tiered test formats and distributor partnerships will remain important for expanding penetration through 2030.
Middle East and Africa
Middle East and Africa demand is concentrated in institutional livestock surveillance, selected urban companion-animal markets, and field-based disease screening. South Africa, Saudi Arabia, and the UAE represent the named regional markets. Infrastructure limitations, supply reliability, and training shortages constrain broader rapid-test adoption across lower-income markets. Zoonotic disease monitoring and livestock-health programs create the clearest near-term demand opportunities. Portable tests offer a practical advantage where centralized laboratory access is limited, but adoption remains dependent on veterinary-service coverage.
GMI Analyst View
Regional divergence will remain pronounced through 2035. North America will retain the largest revenue base because of practice density and companion-animal spending, while Asia Pacific will gain share through higher growth in pet ownership, surveillance investment, and local manufacturing. Europe will remain commercially important because regulation supports structured testing demand. Emerging markets will not follow a uniform adoption path: urban clinics will adopt accessible rapid-kit formats first, while rural growth will depend on public programs and distribution infrastructure.
Veterinary Rapid Tests Market Share & Competitive Landscape
The veterinary rapid tests market is moderately concentrated. IDEXX Laboratories held an estimated 16.7% share of global revenue in 2025, while IDEXX Laboratories, Zoetis, Thermo Fisher Scientific, Virbac, and Heska Corporation (Mars Inc.) collectively held 51.4%. The leadership group combines broad product portfolios, established veterinary relationships, distribution reach, and regulatory capability.
IDEXX Laboratories remains the market leader through its SNAP® test family, SNAP® Pro reader, broader in-clinic diagnostics, reference laboratories, practice-management software, and imaging ecosystem. This combination creates switching costs for practices that already rely on integrated IDEXX workflows. Zoetis leverages longstanding therapeutic and vaccine relationships to expand Vcheck diagnostics in companion-animal and livestock channels. Thermo Fisher Scientific provides reagent, assay, and life-science supply-chain capabilities that support its own veterinary activity and upstream component supply to smaller manufacturers.
Virbac has commercial depth across Europe, Latin America, and Asia Pacific. Heska Corporation operates within Mars Petcare following its December 2021 acquisition, with Element DC5x®, Element i+®, and Solo Step CH Canine Heartworm Antigen Test supporting its reader-based and rapid-kit presence. Primary research from Q1 2026 conversations with 40 veterinary product distributors across North America, Europe, and Asia Pacific identified product breadth, regulatory certification coverage, and regional service responsiveness as the leading supplier-selection criteria.
Recent Industry Developments
May 2025: IDEXX Laboratories announced commercial expansion of SNAP® multiplex testing capabilities for canine respiratory pathogens, including *Bordetella bronchiseptica* and canine influenza virus. The development broadens same-visit respiratory diagnostic options for North American and European clinics.
Mar 2025: Zoetis expanded its Vcheck diagnostic analyzer platform with NT-proBNP and cardiac troponin I panels for dogs. The addition extends rapid in-clinic testing into companion-animal cardiology.
Jan 2025: BioNote received regulatory clearance in South Korea and multiple Southeast Asian markets for expanded Anigen Rapid applications, including FeLV/FIV co-infection detection. The clearance supports wider feline diagnostic access in Asia Pacific.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.